Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiniferatoxin for Intractable Cancer Pain
NCT04572776Phase 3Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 3, randomised, open-label trial of resiniferatoxin in cancer pain, sponsored by Sorrento Therapeutics. Primary endpoint: Change in worst pain as assessed using the Numeric Pain Rating Scale (NPRS) at 4 weeks. Planned start Dec 2020; status: withdrawn.
02
Drugs
resiniferatoxin
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT04572776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572776.